References
- Freeman C, Berg J W, Cutler S J. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29: 253–260
- Isaacson P G, Norton A J. Malignant lymphoma of the upper aerodigestive tract. Extranodal Lymphomas, P G Isaacson, A J Norton. Churchill Livingstone, London 1994; 193–215
- Otter R, Gerrits W BJ, Sandt M M, et al. Primary extranodal and nodal non-Hodgkin's lymphoma: A survey of a population-based registry. Eur J Cancer Clin Oncol 1989; 25: 1203–1210
- Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997; 8: 727–737
- Peh S C. Host ethnicity influences non-Hodgkin's lymphoma subtype frequency and Epstein-Barr virus association rate: the experience of a multi-ethnic patient population in Malaysia. Histopathology 2001; 38: 458–465
- Sukpanichnant S. Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization Classification. Hum Pathol 2004; 35: 224–230
- Hanna E, Wanamaker J, Adelstein D, et al. Extranodal lymphomas of the head and neck. A 20-year experience. Arch Otolaryngol Head Neck Surg 1997; 123: 1318–1323
- Shima N, Kobashi Y, Tsutsui K, et al. Extranodal non-Hodgkin's lymphoma of the head and neck. A clinicopathologic study in the Kyoto-Nara area of Japan. Cancer 1990; 66: 1190–1197
- Kirsch J P, Miller R H, Blair P A. Histiocytic non-Hodgkin's lymphoma of Waldeyer's ring. Otolaryngol Head Neck Surg 1991; 105: 777–780
- Jacobs C, Hoppe R T. Non-Hodgkin's lymphomas of head and neck extranodal sites. Int J Radiat Oncol Biol Phys 1985; 11: 357–364
- Shimm D S, Dosoretz D E, Harris N L, et al. Radiation therapy of Waldeyer's ring lymphoma. Cancer 1984; 54: 426–431
- Yong W, Zhang Y, Zheng W, et al. Prognostic factors and therapeutic efficacy of combined radio-chemotherapy in Waldeyer's ring non-Hodgkin lymphoma. Chin Med J 2000; 113: 148–150
- The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
- Peh S C, Shaminie J, Jayasurya P, et al. Spectrum of malignant lymphoma in Queen Elizabeth Hospital, Sabah. Med J Malaysia 2003; 58: 546–555
- Alizadeh A A, Eisen M B, Davis R E, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
- Hans C P, Weisenburger D D, Greiner T C, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
- Rosenwald A, Wright G, Chan W C, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Eng J Med 2002; 346: 1937–1947
- Chang C C, McClintock S, Cleveland R P, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464–470
- Thompson M P, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10: 803–821
- Sisk E A, Bradford C R, Carey T E, et al. Epstein-Barr virus detected in a head and neck squamous cell carcinoma cell line derived from an immunocompromised patient. Arch Otolaryngol Head Neck Surg 2003; 129: 1115–1124
- Saez A I, Saez A J, Artiga M J, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004; 164: 613–622
- Kuze T, Nakamura N, Hashimoto Y, et al. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(−) cases in Japanese population. Jpn J Cancer Res 2000; 91: 1233–1240
- Young L S, Rickinson A B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757–768
- Gatter K C, Warnke R A. Diffuse large B-cell lymphoma. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue, E S Jaffe, N L Harris, H Stein, et al. IARC Press, Lyon 2001; 171–174
- Oh Y H, Park C K. Prognostic evaluation of nodal diffuse large B-cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci 2006; 21: 397–405
- Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84
- López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma: Clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005; 23: 2797–2804
- De Paepe P, Achten R, Verhoef G, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005; 23: 7060–7068
- Skinnider B F, Horsman D E, Dupuis B, et al. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999; 30: 803–808
- Rantanen S, Monni O, Joensuu H, et al. Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 2001; 42: 1089–1098
- Barrans S, Carter I, Owen R, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143
- Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87: 265–272
- Kramer M HH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152–3162
- Iqbal J, Neppalli V T, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-Cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961–968
- Burns B, Warnke R, Doggett R, et al. Expression of a T-cell antigen (Leu 1) by B-cell lymphomas. Am J Pathol 1983; 113: 165–171
- Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815–821
- Kroft S, Howard M, Picker L, et al. De novo CD5+ diffuse large B-cell lymphomas—a heterogeneous group containing an unusual form of splenic lymphoma. Am J Clin Pathol 2000; 114: 523–533
- Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5– with CD10+ groups may constitute clinically relevant subtypes. Leukemia 1999; 13: 1441–1447
- Assanasen T, Wannakrairot P, Keelawat S, et al. Extranodal malignant lymphoma of the upper aerodigestive tract: Prevalence of Epstein-Barr virus (EBV) infection in King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2005; 88: S266–S273
- Park S, Lee J, Ko Y H, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 972–978
- Isaacson P G, Muller Hermelink H K, Piris M A, . Extranodal marginal zone lymphoma of muocsa-associated lymphoid tissue (MALT lymphoma). World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue, E S Jaffe, N L Harris, H Stein, et al. IARC Press, Lyon 2001; 157–160
- Feller A C, Diebold J. Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas. 3rd ed. Springer, Berlin 2004